Ibudilast
- Generic Name
- Ibudilast
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N2O
- CAS Number
- 50847-11-5
- Unique Ingredient Identifier
- M0TTH61XC5
- Background
Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the...
- Indication
For the treatment of multiple sclerosis, asthma, and cerebrovascular disease.
- Associated Conditions
- -
- Associated Therapies
- -
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 255
- Registration Number
- NCT01982942
- Locations
- 🇺🇸
University at Buffalo, The State University of New York, Buffalo, New York, United States
🇺🇸Cornell Medical College, New York, New York, United States
🇺🇸University of Virginia Charlottesville, Charlottesville, Virginia, United States
Trial of Ibudilast for Methamphetamine Dependence
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 125
- Registration Number
- NCT01860807
- Locations
- 🇺🇸
UCLA Vine Street Clinic, Los Angeles, California, United States
Ibudilast in the Treatment of Patients With Chronic Migraine.
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Parisa Gazerani
- Target Recruit Count
- 33
- Registration Number
- NCT01389193
- Locations
- 🇦🇺
School of Medical sciences, University of Adelaide, Adelaide, Australia
Ibudilast in the Treatment of Medication Overuse Headache
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- University of Adelaide
- Target Recruit Count
- 40
- Registration Number
- NCT01317992
- Locations
- 🇦🇺
Pain and Anaesthesia Research Clinic, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.